



2020-21

Corp. Off.: DLF Tower B, 7th Floor, 710-712,
Jasola District Centre, New Delhi-110025, INDIA
Tel +011-46106858/69
CIN No. U00304HP2005PTC029451
E-mail: info@biodealpharma.com
www.biodealpharma.com

BOARD'S REPORT

Dear Members,

Your Directors are pleased to present their 16th Annual Report together with the Audited Statements of Accounts for the financial year ended 31st March 2021.

1. THE STATE OF COMPANY'S AFFAIRS

A. FINANCIAL HIGHLIGHTS

The summarized results for the financial year ended 31st March 2021 are given below:

PARTICULARS	FOR THE YEAR ENDED 31.03.2021	FOR THE YEAR ENDED 31.03.2020
Total Revenue	536,639,842	516,618,072
Less: Expense	(487,170,932)	(496,625,979)
Profit / Loss Before Tax	49,468,909	19,992,093
Tax Expenses		
Current Tax	0	0
Deferred Tax	12,450,334	5,031,611
Excess / Short Provisions relating earlier year tax	0	0
Profit / (Loss) After Taxation	37,018,575	14,960,482
Balance carried to Balance Sheet	37,018,575	14,960,482

B. RESULTS OF OPERATIONS

The Key highlights pertaining to the business of the company for the financial year ended March 31, 2021 have been given hereunder:


During the period under review, the Company earned a profit of Rs. 37,018,575 /- as compared to profit for the last financial Year of Rs. 14,960,482 /-. The gross revenue for the Financial Year 2020-2021 is Rs. 536,639,842 /- as compared to gross revenue of Rs. 516,618,072 /- in previous Financial Year.

2. THE AMOUNT, IF ANY, WHICH IT RECOMMENDS SHOULD BE PAID BY WAY OF DIVIDEND

The Board of Directors of the Company has not recommended any dividend for the financial year ending March 31, 2021.

3. THE AMOUNTS, IF ANY, WHICH IT PROPOSES TO CARRY TO ANY RESERVES

The Company had transferred the amount of Rs. 37,018,575 /- being the profit for the current year to the general reserve in the balance sheet during the financial year ended 31st March, 2021.



4. CAPITAL STRUCTURE

There is no change in the authorized & Paid up share capital during the period under review.

The **Authorized Share Capital** of the Company is Rs. 250,000,000/- (Rupees Twenty Five Crores only) divided into 25,000,000 (Two Crore Fifty Lacs only) Equity Shares of Rs. 10/- each.

The **Paid up Share Capital** of the Company is Rs. 250,000,000/- (Rupees Twenty Five Crores only) divided into 25,000,000/- (Two Crore Fifty Lacs only) Equity Shares of Rs. 10/- each.

Other mandatory disclosures as per Companies Act, 2013 are provided hereunder:

Issue of Equity Shares with Differential Rights:-

During the financial year ended 31st March, 2021, the Company has not issued any Equity Shares with Differential Rights.

Issue of Employee Stock Options:-

During the financial year ended 31st March, 2021, the Company has not issued any Employee Stock Options as stated in Section 62(1)(b) of the Companies Act, 2013 and Rule 12(9) of Companies (Share Capital and Debenture Rules, 2014).

Issue of Sweat Equity Shares:-

During the financial year ended 31st March, 2021, the Company has not issued any sweat equity shares as specified in Section 54 of the Companies Act, 2013 and Rule 8(13) of Companies (Share Capital and Debenture Rules, 2014).

5. STATE OF COMPANY'S AFFAIRS

Brief description of the nature of business of the company


The Company is into the business to manufacture, produce, process, prepare, sale, import, export and deals in all kinds of commercial activities related to pharmaceuticals and chemical products of medicaments in all its branches.

6. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES

During the year, no Company has become or ceased to be Subsidiaries, Joint Ventures or Associate Companies of the Company.

7. PERFORMANCE AND FINANCIAL POSITION OF THE SUBSIDIARY COMPANIES

During the year, no Company has become or ceased to be Subsidiaries Companies of the Company.



8. CONSOLIDATED FINANCIAL STATEMENT

Since the Company is not having any Subsidiaries, Joint Ventures or Associate Companies therefore provision related to consolidation of financial statements is not applicable.

9. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

There is no material changes and commitments affecting the financial position of the Company which have occurred between the end of the Financial Year of the Company to which the financial statements relate and the date of the report.

10. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO

The information relating to the Conservation of energy, technology absorption and foreign exchange earnings and outgo as required under Rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed as Annexure I and forms part of this report.

11. POLICY ON PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

The Company has zero tolerance for Sexual Harassment at workplace and has adopted and laid down a policy on prevention of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. The policy aims to provide protection to employees at the workplace and prevent redress complaints of sexual harassment and for matters connected or incidental thereto, with the objective of providing a safe working environment, where employees feel secure. The Internal complaint committee known as Prevention of Sexual Harassment (POSH) Committee has also been formed by the Directors to inquire into the complaints of sexual harassment and recommend the appropriate actions, if any.


Your company is fully committed to protect the rights of any women, of any age, whether employed or not, who alleges to have been subjected to any act of sexual harassment within the Company's premises. Your Company provides a safe and healthy work environment.

However, there were no cases reported otherwise, during the year ended on March 31, 2021 of sexual harassment.

12. RISK MANAGEMENT POLICY

The Company has adequate risk management plans and processes in place that commensurate with the size of its business operations. The Management of your Company has devised proper strategies to apprehend risks, take timely actions to mitigate them and convert them to opportunities for the Company.

13. CORPORATE SOCIAL RESPONSIBILITY



Pursuant to the provisions of Section 135 of the Companies Act 2013, every Company having net worth of Rupees Five Hundred Crore or more, or turnover of Rupees One Thousand Crore or more or a net profit of Rupees Five Crore or more during any financial year shall constitute a Corporate Social Responsibility Committee of the Board consisting of three or more directors, out of which at least one director shall be an Independent Director. Since the provisions of section 135 of the Companies Act, 2013 were not applicable on the company for the period ended as at March 31, 2021, the company has not developed or implemented any policy on Corporate Social Responsibility and subsequently no initiatives taken during the year.

14. VIGIL MECHANISM

The provisions regarding vigil mechanism as provided in Section 177(9) of the Companies Act, 2013 read with rules framed there under are not applicable on the Company.

15. HUMAN RESOURCES AND INDUSTRIAL RELATIONS

The Company is pleased to report that during the year under reporting, the relations were cordial.

16. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE COMPANIES ACT, 2013

Loans, Investments and guarantee Covered under Section 186 of the Companies Act, 2013 form the part of the notes to the financial statements provided in this Annual report.

17. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES REFERRED TO IN SECTION 188(1)


During the period there are contracts or arrangements entered with related parties referred to in the provision of the Section 188(1) of the Companies Act, 2013 which are attached as **Annexure I** to this report.

18. NUMBER OF MEETINGS OF THE BOARD

The Board duly met 10 times in Financial Year 2020-21; on 01st July, 2020; 01st September, 2020; 25th September, 2020; 24th November, 2020; 10th December, 2020; 18th December, 2020; 19th January, 2021; 01st February, 2021; 24th March, 2021 and 30th March, 2021.

The provisions of Companies Act, 2013 and Secretarial Standards issued by Institute of Company Secretaries of India were adhered to, while considering the time gap between two meetings. Also proper notices were given and the proceedings were properly recorded, signed and maintained in the Minutes book kept by the Company for the purpose.

Names of Director's on the Board, their attendance at Board Meetings during the financial year 2020-21 is as follows:



Name	Designation	No. of Board Meetings Attended
Mr. Gunjan Kumar	Director	10
Mr. Subodh Prasad Singh	Director	10
Mr. Anurag Kumar	Director	4

19. COMMITTEE'S OF THE BOARD

The Company was not required to constitute any committees of the board under the provisions of the Companies Act, 2013 during the financial year under review.

20. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors' states that:

(a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis;

(e) the directors had devised proper systems to ensure compliances with the provisions of all applicable laws and that such systems were adequate and operating effectively.

21. CHANGE IN THE NATURE OF BUSINESS, IF ANY


During the year, your Company has not changed the nature of its business.

22. DEPOSITS

The Company has not accepted any deposits during the year pursuant to the provisions of Chapter V of the Companies Act, 2013.

1. The details relation to deposits accepted under Chapter V of the Act are as follows:

- a) Accepted during the year - NIL
- b) Remained unpaid or unclaimed as at the end of the year - NIL
- c) Whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved - NA
 - (i) At the beginning of the year - Nil
 - (ii) Maximum during the year - Nil
 - (iii) at the end of the year - Nil



2. The details of deposits which are not in compliance with the requirements of Chapter V of the Act - NA

23. LOAN TAKEN FROM DIRECTOR OR THEIR RELATIVE

The loan taken from Director forms the part of the notes to the financial statements.

24. DIRECTORS & KEY MANAGERIAL PERSONNEL (KMP)

Details of Directors and KMPs who were appointed or resigned during the year

During the year, there are following changes in the composition of the Board of Directors of the company during the Financial Year:

- a) Ms. Marisha Mahana was resigned from the post of Company Secretary w.e.f. 25th August, 2020;
- b) Ms. Swati Tiwari was appointed as Company Secretary of the Company w.e.f. 01st September, 2020.
- c) Mr. Anurag Kumar has been regularised as Director of the Company in the Annual General Meeting of the Company held on 31st December, 2020.
- d) Mr. Gunjan Kumar was resigned from the post of Directorship w.e.f. 01st February, 2021.

Declaration by the Independent Directors

The Company being the Private Company, the appointment of Independent Director is not mandatory.

25. AUDITORS

The members are informed that pursuant to the provisions of Section 139 read with the Companies (Audit and Auditors) Rules, 2014; M/s Joshi Vishal & Associates, (Chartered Accountants), Chandigarh have been appointed as Statutory Auditor of the Company, who shall hold office till the conclusion of Annual General Meeting to be held in the Calendar year 2024.


AUDITOR'S REPORT

The statements of the Auditor are explanatory and do not require any further clarification and explanation.

COST AUDITOR FOR FINANCIAL YEAR 2020-21

Your Company has appointed M/s JSN & CO. as Cost Auditor for FY 2020-21.

Your Company is maintaining Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014, specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013.



SECRETARIAL AUDITOR FOR FINANCIAL YEAR 2020-21

Your Directors wish to inform that the Secretarial audit was not applicable to the company during the Financial Year 2020-21.

26. MATERIAL ORDERS BY GOVERNING AUTHORITIES

There were no significant or material orders passed by any governing authority of the Company including regulators, courts or tribunals which could impact the going concern status and company's operations in future.

27. ADEQUACY OF INTERNAL FINANCIAL CONTROL WITH RESPECT TO THE FINANCIAL STATEMENT

The Company has an adequate internal financials control with reference to the financial statement. During the year hence no reportable material weakness in the design or operations were observed.

28. OPERATIONS

Your company's operations were running smoothly during the year.

29. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUBSECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT

There are no frauds reported by Auditors under subsection (12) of Section 143.

30. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES DETAILS PURSUANT TO SECTION 197(12) READ WITH RULE 5 OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014


Since the company is not a listed company, provision of section 197(12) is not applicable on the company.

31. ACKNOWLEDGEMENT

Your Board of Directors wish to thank and place on record their appreciation for the co-operation and support extended to the Company by the Government of India, Reserve Bank of India, Other Local Authorities, Bankers, Suppliers, Customers, Distributors, Employees and other Stakeholders which have been a constant source of strength to the Company.

The Board of Directors also expresses its sincere gratitude to all the shareholders for their continuous support and trust they have shown in the management. The dedication and sense of commitment shown by the employees at all levels during the year deserve special mention.

For and on behalf of the Board of Directors of



Biodeal Pharmaceuticals Private Limited
For Biodeal Pharmaceuticals Pvt. Ltd.



Director

Name: Anurag Kumar
Designation: Chairperson & Director
DIN: 08598700
Address: House No. 793, Sector 3-D
Bokaro Steel City, Bokora
Jharkhand-827001

Place: Delhi
Date: 18/10/2021

ANNEXURE - I

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO

A. CONSERVATION OF ENERGY

- 1) the steps taken or impact on conservation of energy: NIL
- 2) the steps taken by the company for utilizing alternate sources of energy: NIL
- 3) the capital investment on energy conservation equipment's: NIL


B. TECHNOLOGY ABSORPTION

- 1) the efforts made towards technology absorption: NIL
- 2) the benefits derived like product improvement, cost reduction, product development or import substitution: NIL
- 3) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): NIL
- 4) the expenditure incurred on Research and Development: NIL

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

On accrual basis, following is the relevant information:

S. No.	OTHER DISCLOSURES	As at 31.03.2021	As at 31.03.2020
		Amount (Rs.)	Amount (Rs.)
1	Expenditure in Foreign Currency	14,09,35,407	9,92,51,027
2	Earning in Foreign Currency	8,75,55,963	7,42,37,131



Annexure II

FORM NO. AOC -2

Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014


Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of Section 188 of the Companies Act, 2013 including certain arms' length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

S. No.	Particulars	Details
a)	Name(s) of the related party & nature of relationship	-
b)	Nature of contracts/ arrangements/ transaction	-
c)	Duration of the contracts/ arrangements/ transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	-
e)	Justification for entering into such contracts or arrangements or transactions	-
f)	Date of approval by the Board	-
g)	Amount paid as advances, if any	-
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	-

2. Details of contracts or arrangements or transactions at Arm's Length basis:-


S. No.	Particulars	Detail	Detail	Detail	Detail
a)	Name(s) of the related party & nature of relationship	Laboster Overseas (Associated Firm)	Laboster Overseas (Associated Firm)	Atlantas Worldwide Pvt Ltd (Associated Company)	Xenone Healthcare Pvt. Ltd (Associated Company)
b)	Nature of contracts/ arrangements/ transactions	Sales	Purchase	Services	Sales
c)	Duration of the contracts/ arrangements/ transactions	As per agreement	As per agreement	As per agreement	As per agreement
d)	Salient terms of the contracts or arrangements or transactions including the value, if any:	Rs. 16,68,614	Rs. 52,68,300	Rs. 75,06,131	Rs. 27,11,033
e)	Date of approval by	Not	Not		Not



	the Board, if any:	Applicable	Applicable		Applicable
f)	Amount paid as advances, if any	Not Applicable	Not Applicable		Not Applicable

**For and on behalf of the Board of Directors of
Biodeal Pharmaceuticals Private Limited**

For Biodeal Pharmaceuticals Pvt. Ltd.


Director

Name: Anurag Kumar
Designation: Chairperson & Director
DIN: 08598700
Address: House No. 793, Sector 3-D
Bokaro Steel City, Bokora
Jharkhand-827001

Place: Delhi
Date: 18/10/2021